Body fatness and bevacizumab-based therapy in metastatic colorectal cancer

Gut

Volumn 59, Issue 3, 2010, Pages 289-290

  Renehan, Andrew G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; K RAS PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANTHROPOMETRY; BODY FAT; BODY MASS; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTRAABDOMINAL FAT; METASTASIS; NOTE; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE SIZE; SUBCUTANEOUS FAT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BODY MASS INDEX; COLORECTAL NEOPLASMS; HUMANS; OBESITY; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77749321736     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.197210     Document Type: Note

References (10)

1. Renehan A, Tyson M, Egger M, et al. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-78.
2. Renehan AG, Roberts DL, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem 2008;114:71-83.
3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;48):579-91.
4. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003;98:484-95.
5. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:1647-54.
6. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based therapy in metastatic colorectal cancer. Gut 2010;59:341-7.
7. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
8. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009;58:718-25.
9. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008;8:592-603.
10. Silha JV, Krsek M, Sucharda P, et al. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005;29:1308-14.